Recently, Salubris announced that its clinical trial application for SAL0167 (project code: SAL0167), a proprietary innovative drug candidate for the treatment of hyperlipidemia, has been accepted for review[1].
SAL0167 is a cyclic peptide developed by the company with fully independent intellectual property rights. As a cyclic peptide, SAL0167 exhibits high affinity and specificity for its target, positioning it as a potential preferred treatment option for hypercholesterolemia, particularly in patients requiring potent lipid-lowering therapy.
If successfully developed and approved, SAL0167 is expected to offer patients with a new treatment option, improve patient compliance, address unmet clinical needs, and further enrich the company’s innovative product pipeline in the CKM (Cardiovascular-Kidney-Metabolic) therapeutic area, with a primary focus on cardiovascular diseases.
About cyclic peptides[2-3]：
As a novel therapeutic modality bridging small-molecule drugs and antibody drugs, cyclic peptides combine the core advantages of both: they retain the high activity, high selectivity, and favorable safety profile of antibodies, while also offering the low production cost, excellent stability, and potential for oral administration characteristic of small-molecule drugs. This makes them an important breakthrough direction in current drug R&D.
References：
[1] Shenzhen Salubris Pharmaceuticals Co., Ltd. Announcement regarding acceptance of the clinical trial application for SAL0167.
[2] Gang D, Kim DW, Park H-S. Cyclic Peptides: Promising Scaffolds for Biopharmaceuticals. Genes. 2018; 9(11):557.
[3] Atangcho L, Navaratna T, Thurber GM. Hitting Undruggable Targets: Viewing Stabilized Peptide Development through the Lens of Quantitative Systems Pharmacology. Trends in Biochemical Sciences. 2018; 44: 241-257.
Disclaimer：
1. This material is intended solely to provide knowledge about the disease area and increase disease awareness. It is not for promotional purposes.
2. The information contained in this material is for reference only. Please follow the advice or guidance of a physician or other healthcare professional.
|About Salubris
Shenzhen Salubris Pharmaceuticals Co., Ltd., founded in 1998, is an innovation-driven pharmaceutical company listed on the Shenzhen Stock Exchange (stock code: 002294). Operating with an integrated R&D, manufacturing, and sales platform, Salubris is committed to its mission: “To provide outstanding pharmaceutical products for human health.” The company focuses on the CKM (cardiovascular-kidney-metabolic) chronic disease therapeutic area, with a special emphasis on cardiovascular diseases. It has launched several original drugs, including Xinlitan®, Fulitan®, Fulian® and Xinchaotuo® for hypertension; Ennaluo® for renal anemia; and Xinliting® for type 2 diabetes.
Salubris operates five global innovative drug R&D centers and three medical device R&D hubs. It has built innovation platforms covering small molecule chemical drugs, biologics, siRNA and gene-editing therapeutics, and medical devices, all dedicated to addressing unmet clinical needs and improving people’s quality of life.
